Natera (NTRA)
Health Care · molecular diagnostics · NASDAQ
Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
What Natera does
Natera is a diagnostic company that develops and commercializes genetic testing services, focusing primarily on women’s health, oncology, and organ health. Its core product portfolio includes non-invasive prenatal testing (NIPT), carrier screening, and molecular residual disease (MRD) testing for cancer monitoring. The company operates through a mix of direct sales and collaborative partnerships with medical institutions and laboratory partners.
Themes: molecular diagnostics, women's health / reproductive health, oncology / cancer monitoring, liquid biopsy, genetic testing, organ transplant health
Fundamentals
- Price$332.03 as of 2026-08-21 close
- Market cap$47.9B as of 2026-08-21
- 1-year return+105.0% 2025-08-21 close $161.95 → 2026-08-21 close $332.03
- P/En/a negative earnings
- Net margin-7.1% as of 2026-08-24
- Gross margin+65.2% as of 2026-08-24
- ROE-11.7% as of 2026-08-24
- Debt / equity0.04 as of 2026-08-24
- Revenue growth (YoY)+37.8% as of 2026-08-24
- Revenue CAGR (3y)+41.1% SEC XBRL
- Beta1.56 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How NTRA compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NTRA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
49.6 #813 of 1,704 scored · #142 of 240 in Health Care
Trend 83rd: it is trading 21.8% above its 50-day average, the short-term trend line; catalysts 75th: analysts have raised their average price target by 16.9% since the prior reading; weakest is setup 15th: no Elliott-wave labelling currently fits its swings. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Natera looks technically
Natera (NTRA) is trading 44.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is trading at or near its all-time high.
Trend
8
| Distance from the 200-day | it is trading 44.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +44.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $272.65 | $272.65 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $229.12 | $229.12 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 305. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal | 53 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control | 36.2 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 72, in overbought territory (above 70) | 72.1 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($263.55 to $333.52) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 97.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $333.52 | $333.52 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.5% |
| Above the 52-week low | it is 111.9% above its 52-week low (its lowest price of the past year) | +111.9% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.5% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $333.52 (set on 2026-08-20) | $333.52 |
| Given back of the 52-week move | over the past year its closes ranged ($160.12 to $332.03), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $220.29 to $225.79. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is trading at or near its all-time high | -0.5% |
| Nearest price level | it is trading 25.2% above a support level at $248.31 — a price it turned at three times since 2025-12-08, most recently on 2026-07-29. Since 2024-08-21 it has 11 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -25.2% |
| All-time low | its lowest closing price on record is $6.52 (set on 2016-02-08) | $6.52 |
| Above the all-time low | it is 4992.5% above its all-time low | +4,992% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 93% of the past ~6 months) | 93rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $12.73 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $12.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $239.69 and $348.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $239.69 – $294.23 – $348.78 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 8.1 daily ranges above its 200-day average price (44.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.96× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.8% since the prior reading | +1.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.1% |
|---|---|---|
| Open gap | it gapped 3.0% above the previous close 2 sessions ago and has not traded back through the level it left behind at 311.69 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.0% |
| Gap filled | a 2.5% gap down opened on 2026-08-06 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 21.9 percentage points (the stock gained 24.3% while the market gained 2.3%) | +21.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 59.9 percentage points (the stock gained 63.0% while the market gained 3.1%) | +59.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 45.5 percentage points (the stock gained 56.5% while the market gained 11.1%) | +45.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 84.5 percentage points (the stock gained 105.0% while the market gained 20.5%) | +84.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 27% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.6% of the share price. | +26.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 43% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $231.69 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +43.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $314.48 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +5.6% |
Price levels it has turned at before
NTRA last closed at $332.03 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $248.31 | Support | 25.2% below the last close | turned there three times · 2025-12-08 to 2026-07-29 |
| $226.63 | Support | 31.7% below the last close | turned there three times · 2026-01-02 to 2026-06-04 |
| $221.02 | Support | 33.4% below the last close | turned there four times · 2025-12-17 to 2026-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $305.00.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $368.80 and $472.03 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 21 analysts
- Mean price target$336.74 range $280.00 – $375.00; median $348.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NTRA
- Consensus EPS estimate-$0.244 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on a limited number of core products (Signatera, Panorama, Horizon) for a significant portion of revenue.","Ongoing litigation regarding intellectual property and regulatory matters.","Dependence on third-party payer coverage and reimbursement policies for financial success."]
What changed in the latest 10-Q
AI-assisted comparison of NTRA's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to Form 10-K for year ended December 31, 2025, filed February 27, 2026 (newer filing)
- Added mention of Boulder, Colorado laboratory for clinical trials testing
- Added Fetal Focus, Vistara, and Anora to women's health product offerings in overview
- Added Latitude blood-based MRD test for colorectal cancer to oncology offerings
- Added Altera comprehensive genomic profiling test to oncology offerings
- Added statement that Empower is 'also offer[ed] through our oncology sales channel'
- Added three-month period data: 1,013,600 tests processed (999,200 accessioned) for Q1 2026 vs 855,100 tests (840,800 accessioned) for Q1 2025
- Added Q1 2026 revenue figures: $696.6 million total revenues and $693.9 million product revenues
- Added Q1 2025 revenue figures: $501.8 million total revenues and $500.0 million product revenues
- Added U.S. laboratory distribution partners revenue attribution: 3% for Q1 2026 vs 2% for Q1 2025
- Added international revenues: $11.0 million (2%) for Q1 2026 vs $9.5 million (2%) for Q1 2025
- Added Q1 2026 net loss figure: $85.1 million and stock compensation: $95.1 million
- Added Q1 2025 net loss figure: $66.9 million and stock compensation: $77.8 million
- Added accumulated deficit as of March 31, 2026: $2.9 billion
- Removed:
- Removed reference to Form 10-K for year ended December 31, 2024, filed February 28, 2025 (older filing)
- Removed mention of Spectrum preimplantation genetic testing for IVF embryo screening
- Removed mention of Prospera transplant rejection assessment test
- Removed statement that Signatera was 'commercialized as a test run in our CLIA laboratory and offer[ed] on a research use only basis'
- Removed statement that Empower was planned 'to offer to oncologists through our oncology sales channel'
- Removed nine-month period data for September 30, 2025 and 2024
- Removed nine-month revenue figures and comparisons
- Removed nine-month net loss and stock compensation figures
- Removed accumulated deficit figure as of September 30, 2025
- Reworded:
- Changed cfDNA description from 'or cfDNA' to '(cfDNA)' in parenthetical
- Changed product suite description from 'currently provide a comprehensive suite of products in women's health, oncology and organ health, as well as our Constellation cloud-based platform' to 'provide a comprehensive suite of products to improve patient care outcomes in three main areas of healthcare – oncology, women's health, and organ health'
- Changed women's health products description from 'also include Spectrum preimplantation genetic testing, our IVF embryo screening; Anora, our test to help determine underlying reasons for occurrence of miscarriage, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Fetal Focus, our noninvasive prenatal test for inherited conditions' to 'include Fetal Focus, our noninvasive prenatal test for single-gene inherited conditions, Vistara, our single-gene NIPT that screens for conditions that may affect quality of life, and Anora, our test to help determine underlying reasons for occurrence of miscarriage, and Empower, our hereditary cancer screening test which we also offer through our oncology sales channel'
- Removed organ health Prospera test from product descriptions
- Changed oncology description from 'in addition to Horizon, we also offer Empower, our hereditary cancer screening test, which we also plan to offer to oncologists through our oncology sales channel; and Signatera, our molecular residual disease test for oncology applications, which we commercialized as a test run in our CLIA laboratory and offer on a research use only basis to research laboratories and pharmaceutical companies' to 'we offer Signatera, our personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer. We also offer Latitude, our blood-based MRD test for colorectal cancer that does not require a tumor tissue sample, as well as Altera, a comprehensive genomic profiling test to support treatment decisions and therapy selection'
- Changed laboratory location description from 'in Austin, Texas and San Carlos, California' to 'primarily in Austin, Texas and San Carlos, California; our laboratory in Boulder, Colorado performs clinical trials testing'
- Changed test accessioning definition from 'we accession when a sample is received, entered into our computer system, and routed for processing' to 'is accessioned when we receive the test at our laboratory, the relevant information about the test is entered into our computer system, and the test sample is routed into the appropriate workflow'
- Changed language about test volume metrics from 'It is a subset of total tests processed, which also includes tests distributed through our Constellation licensees' to 'This number is a subset of the number of tests that we process'
- Changed statement about Constellation transition from 'As our laboratory partners transition to our cloud-based distribution model, accessioned tests will decrease while processed tests continue to reflect overall volume growth' to new explanation that Constellation 'results in lower revenues and gross profit per test than cases in which we process a test ourselves; however, because we do not incur the costs of processing the tests, our costs per test under this model are also lower'
- Changed phrasing from 'Our two primary distribution channels are our direct sales force and our laboratory partners' to 'The principal focus of our commercial operations is to offer our tests through both our direct sales force and laboratory distribution partners'
- Notes:
- Newer filing covers three months ended March 31, 2026 while older filing covers nine months ended September 30, 2025 – different reporting periods make direct volumetric and financial comparisons limited to year-over-year Q1 comparisons only
- The section appears truncated at the end of both filings, with older filing text ending mid-sentence at 'Our two primary d' and newer filing text ending mid-sentence at 'We generate revenues from the sale of our tests, primarily from the sale of our Signatera, Panorama and Horizon tests. Our two primary d'
Risk Factors
- Added:
- In newer filing (2026-05-08): Added phrase 'our expectations regarding acquisitions, dispositions and other strategic transactions and our ability to successfully integrate Foresight Diagnostics, Inc. into our business operations' in forward-looking statements section
- In newer filing (2026-05-08): Reference to Form 10-K for year ended December 31, 2025 filed February 27, 2026
- Removed:
- In older filing (2025-11-07): Phrase 'including our expectations regarding the impact on our business and the regulation of our tests due to the final rule regarding LDTs published by the FDA in May 2024' removed from regulatory requirements bullet point
- In older filing (2025-11-07): 'our expectations regarding acquisitions, dispositions and other strategic transactions' did not include Foresight Diagnostics integration language
- In older filing (2025-11-07): Reference to Form 10-K for year ended December 31, 2024 filed February 28, 2025
- Reworded:
- Order of products listed changed from 'Panorama, Horizon, and Signatera' (2025-11-07) to 'Signatera, Panorama, and Horizon' (2026-05-08)
- Punctuation inconsistency: newer filing omits comma after 'may' in forward-looking statement identifiers ('believe,' 'may' 'will' vs. older 'believe,' 'may,' 'will,')
- Notes:
- Balance sheet section in newer filing appears truncated/incomplete; comparison limited to forward-looking statements section which was fully available in both filings
- The newer filing references December 31, 2025 year-end (consistent with Q1 2026 filing), while older filing references December 31, 2024 year-end (consistent with Q3 2025 filing)
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 146 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 47 sells ($11M) — 7 selling insiders
- Last 90 days0 buys · 146 sells ($83M) — 11 selling insiders
- Last 180 days0 buys · 200 sells ($91M) — 11 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-07. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NTRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for NTRA from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding NTRA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 17,791,538
- Reported value $3,558,129,589
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NTRA had 4,365,205 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NTRA had 3.03% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.69 days to cover at the same settlement.
- Reported short interest (shares) 4,365,205
- Short interest (% of shares outstanding) 3.03%
- Prior settlement (shares) 4,964,646
- Reported change -12.07%
- Days to cover (reported) 4.69
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Illumina (ILMN)
- Exact Sciences (EXAS)
- Guardant Health (GH)
- Invitae (NVTAQ)
- Myriad Genetics (MYGN)
- Laboratory Corporation of America (LH)
- Quest Diagnostics (DGX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NTRA vs…
Natera is found in…
Frequently asked questions
What does Natera (NTRA) do?
Natera is a diagnostic company that develops and commercializes genetic testing services, focusing primarily on women’s health, oncology, and organ health. Its core product portfolio includes non-invasive prenatal testing (NIPT), carrier screening, and molecular residual disease (MRD) testing for cancer monitoring. The company operates through a mix of direct sales and collaborative partnerships with medical institutions and laboratory partners.
What sector is Natera (NTRA) in?
Natera (NTRA) is classified in the Health Care sector. Its industry is molecular diagnostics. It trades on NASDAQ.
Who are Natera's (NTRA) competitors?
Notable peers of Natera (NTRA) include Illumina, Exact Sciences, Guardant Health, Invitae and Myriad Genetics. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in NTRA?
Yes — we hold 3 matched STOCK Act disclosures for NTRA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Natera (NTRA) overbought or oversold right now?
Natera (NTRA) is currently in overbought territory (its 14-day RSI is 72, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NTRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.